Opens in a new tab

Autoimmune and Autoinflammatory Conditions in Individuals with Down Syndrome

Claim your continuing education credit for reading this article by using the link at the bottom of the page.

Introduction

Down syndrome is the result of a third copy of chromosome 21 and occurs in approximately 1 of every 800 births worldwide.[1] In the United States, there are more than 5,000 live births annually and a prevalence of 1 in 1,500 individuals with Down syndrome.[2] Individuals with Down syndrome are at increased risk for a variety of comorbidities across multiple body systems, including an increased prevalence of autoimmune and inflammatory conditions. Further investigation into the immune system of individuals with Down syndrome has identified clear differences resulting in immune system dysregulation, which is central to the increase in autoimmune, autoinflammatory, and infectious conditions in this population. Awareness and early identification are key to initiating appropriate evaluation and treatment to prevent morbidity and mortality.

Immune System Dysregulation

While the exact mechanism and etiology of immune dysregulation have not been fully determined in individuals with Down syndrome, several immune system cells and pathways have been implicated in the cause of immune dysregulation. Knowledge of the different mechanisms of immune dysregulation in people with Down syndrome will benefit clinicians as they associate clinical manifestations with specific abnormalities in the immune system. With improvements in pathway-specific therapies, a more precise approach may be utilized to treat identified abnormalities.

Innate Immune System

There are noticeable differences in monocytes with impaired phagocytosis and chemotaxis, and more sensitivity to interferon signaling in individuals with Down syndrome.[3][4] There is also evidence of altered granulocyte function, specifically seen in neutrophils and innate immune system eosinophils that may result in less effective chemotaxis and bactericidal capabilities, along with shorter survival of granulocytes,[5] which may lead to more illnesses and infections. Toll-like receptors (TLRs) are found on cells in the innate immune system and individuals with Down syndrome have increased expression of TLRs, which may prime the innate immune system to develop autoimmunity.[6] The complement protein C1q has been shown to increase with age in individuals with Down syndrome, which is thought to be due to inflammatory cytokines (IL-6 and IFN-γ) and chronic inflammation.[7]

Adaptive Immune System

Differences in the adaptive immune system between individuals with and without Down syndrome show that those with Down syndrome have decreased absolute numbers of B and T cells in childhood, T cell counts that increase with age and normalize in adulthood, and B cell numbers that remain low with age.[8] In addition to the changes seen in absolute numbers of lymphocytes, there are also imbalances in subpopulations of T helper (Th1, Th2, Th17 and Treg, CD4+) and cytotoxic T cells (CD8+),[9] which lead to increased frequency of proinflammatory cells (Th1 and Th17). There are also differences in lymphocyte function with dysregulation of Treg cells or resistance to Treg cells that may predispose to autoimmunity through weakened immune tolerance.[10] The CD4/CD8 ratio has also been shown to be inverted, which is associated with autoimmune disease.[9]

Pathways Dysregulated in People with Down Syndrome

Multiple studies have shown that most healthy individuals with Down syndrome have elevated inflammatory cytokines at baseline when compared to healthy individuals without Down syndrome. This includes elevation of IL-6, IL-1α, and TNF-β, while a subset also has elevation of IL-2, IL-17, and IFN-γ. These inflammatory profiles are similar to what would be present in an individual with an autoimmune condition or acute illness, and because of this it has been suggested that Down syndrome is a cytokinopathy.[10][11][12] Interferon hyperactivation has also been implicated as a central driver of immune dysfunction due to the increased number of IFN receptors encoded on chromosome 21, which allows for chronic hyperactivation of IFN signaling. This leads to increased cytotoxic T Cells, B cell depletion and monocyte activation.[13] Autoinflammatory interferonopathies, such as Aicardi-Goutières and CANDLE syndrome, represent an expanding group of conditions resulting from increased interferon activation and require therapy that targets the interferon pathway.

Aging is associated with increased autoimmunity and proinflammatory cytokines, and inflammaging describes how the immune system ages and becomes more proinflammatory with age. Individuals with Down syndrome have been shown to have inflammaging, and models show that the immune system of individuals with Down syndrome is on average up to 17 years older than that of individuals without Down syndrome. Inflammaging is also present in children with Down syndrome, so their immune system age is older than their chronologic age and compared to their peers.[14] It has also been demonstrated that individuals with Down syndrome who have a known autoimmune condition have more evidence of inflammaging compared to individuals with Down syndrome without an autoimmune condition.[14] Inflammaging could explain why individuals with Down syndrome develop many autoimmune conditions at earlier ages compared to those without Down syndrome.

Micro RNAs (miRNAs) have been implicated in pathogenic inflammatory signaling pathways that lead to a proinflammatory state, and chromosome 21 is enriched with miRNAs that results in an increased gene dosage effect for individuals with Down syndrome, which may be another explanation for the proinflammatory state of Down syndrome.[15][16] The autoimmune regulator (AIRE) gene, present on chromosome 21, is expressed in thymic cells and is responsible for central tolerance by elimination of autoreactive T cells. It has been shown to have an increased gene dosage effect that alters expression and leads to predisposition to autoimmune disease.[17][18]

Down syndrome has been a model of primary immunodeficiency due to the defects seen in B cell differentiation that lead to decreased memory B cells, which can resemble common variable immunodeficiency (CVID).[19] However, in contrast to CVID, individuals with Down syndrome typically have increased IgG levels, normal IgA levels, and decreased IgM and IgE levels. Individuals with Down syndrome have also been shown to have a decreased response to vaccination that declines more rapidly over time (pneumococcal polysaccharide, tetanus, Pertussis, hepatitis B, influenza, and oral polio).[9][20]

Autoimmune Conditions

Celiac Disease

Celiac disease is a Th1-dominant proinflammatory condition that is more prevalent in individuals with Down syndrome, with a 6- to 10-fold increased risk for development compared to the rest of the population.[21] It occurs in 10% of people with Down syndrome and is often diagnosed in childhood, with an average age of 9 years. Due to atypical presentation, there is an average 2.9-year delay in diagnosis. There is currently no set standard when it comes to screening for celiac disease; some recommend regular screening at routine health visits with transglutaminase immunoglobulin A (TTG IgA) and quantitative IgA (to identify IgA deficiency, which invalidates TTG IgA) in individuals with Down syndrome, but others recommend screening for symptoms[22][23][24][22][23][24] For more information on celiac disease in individuals with Down syndrome, see the article, Gastrointestinal Conditions.

Autoimmune Thyroid Disease

Autoimmune thyroid conditions (Hashimoto’s thyroiditis and Graves’ disease) are the most prevalent autoimmune conditions identified in individuals with Down syndrome.[25] Hashimoto’s thyroiditis has a prevalence of 13-46% and is identified in children more often than Graves’ disease. Graves’ disease has a prevalence of 1-6.5%, and is typically seen more often in adults, but is also more common in children with Down syndrome. There is evidence to suggest that those with Hashimoto’s thyroiditis may progress to Graves’ disease over time.[25][26] Both conditions are Th1-dominant proinflammatory conditions that lead to IFN hyperactivity but may also be the result of innate and adaptive immune system dysfunction. Hashimoto’s thyroiditis is associated with antithyroid antibodies, however, at disease onset, there are lower levels of antithyroid antibodies, which can lead to difficulties in diagnosis. Additional unique features of autoimmune thyroid disease in individuals with Down syndrome include equal sex distribution, a lower rate of positive family history, and a higher progression to overt disease from subclinical disease, which is the most common thyroid abnormality seen in individuals with Down syndrome.[27] Due to the high risk for thyroid disease, the American Academy of Pediatrics recommends TSH check at birth, 6 months, 12 months and then annually,[23] and the GLOBAL Medical Care Guidelines for Adults with Down Syndrome recommends a TSH check every 1-2 years beginning at age 21 years.[24]

Type 1 Diabetes

Type 1 diabetes is more prevalent in individuals with Down syndrome compared to the rest of the population, and people with Down syndrome have a 3- to 4-fold increased risk of developing Type 1 diabetes.[21][28] It typically occurs at a younger age for those with Down syndrome compared to the rest of the population. It is a Th1-dominant proinflammatory condition that leads to IFN hyperactivity, which is a likely contributor to the development of Type 1 diabetes.[29]

Autoimmune Dermatologic Disease

Autoimmune skin conditions that occur at a higher prevalence in individuals with Down syndrome include hidradenitis suppurativa (HS; 21%), psoriasis (6%), alopecia (8%), and vitiligo (2%).[30] Individuals with Down syndrome have a 5-fold greater likelihood of developing HS compared to the rest of the population. For those with Down syndrome, HS occurs more frequently in early adulthood (18 – 29 years) with most common locations in the axillae, groin and thighs. It is also identified more in obese and overweight individuals.[31] Compared to the non-Down syndrome population, HS is diagnosed at an earlier age and has an equal sex distribution.[32]

Psoriasis has been reported in 0.5 to 8% of individuals with Down syndrome.[33] Plaque psoriasis is the most common type of psoriasis observed in individuals with Down syndrome and most commonly affects the scalp and extensor extremities.[31]

Alopecia also occurs more frequently in individuals with Down syndrome compared to the non-Down syndrome population with prevalence of 1-11%.[34] It is observed more frequently in males and at younger age, typically prepubertal.[31]

Vitiligo has a prevalence of 3% in individuals with Down syndrome, which is higher than observed in the rest of the population[34] and has been shown to have similar pathogenesis to alopecia with hyperactivation of IFN signaling.[35] Alopecia, psoriasis and vitiligo have all been successfully treated with JAK inhibition.[30] For more information on dermatologic disease in individuals with Down syndrome, see the article, Skin, Hair, and Nail Conditions in Individuals with Down Syndrome.

Down Syndrome-associated Arthritis and Gout

Down syndrome-associated arthritis (DA) is an inflammatory joint disease that typically has onset in childhood and occurs in 2% of individuals with Down syndrome.[36] At presentation it commonly involves multiple small and medium joints, antinuclear antibody and rheumatoid factor tests are typically negative, and early disease often presents with normal laboratory and imaging tests.[37] Elevation in inflammatory markers (such as erythrocyte sedimentation rate) and evidence of joint damage on imaging (bone erosion or joint space narrowing) are only seen if symptoms have been present for many months or years. Historically, DA has been commonly missed or misdiagnosed due to subtleties in presentation, lack of awareness, and innate mechanical issues (such as hypotonia, joint laxity and pes planus) seen in individuals with Down syndrome.[38][39] Treatment typically includes immunosuppression, which presents many additional challenges, but results in improvement over time if tolerated.[37][40] Screening tools have been developed and used to improve awareness and early identification.[36]

Individuals with Down syndrome have been shown to have a greater odds of developing gout compared to controls,[41] and this could be related to the higher levels of uric acid.[42] Careful evaluation of gout is required to confirm the diagnosis through joint fluid analysis, which reveals monosodium urate crystals. Treatment is directed at joint inflammation and the reduction of uric acid.

Down Syndrome Regression Disorder

Down Syndrome Regression Disorder (DSRD) is a neuropsychiatric condition that affects individuals with Down syndrome and presents with a combination of neuropsychiatric symptoms that meet clinical criteria for “possible” and “probable” diagnosis. Individuals with DSRD and specific neurodiagnostic abnormalities can be highly responsive to immunotherapy as immunoglobulin is considered the gold standard immunotherapy treatment at this time.[43] For more information on DSRD, see the article, Down Syndrome Regression Disorder: Clinical Features, Diagnosis and Therapeutics.

Vitamin B12 Deficiency

Vitamin B12 deficiency is more prevalent in individuals with Down syndrome and may be related to autoimmunity or secondary to celiac disease, both of which are more common in individuals with Down syndrome. Vitamin B12 deficiency may present as a neurological or psychological change, and macrocytosis without B12 deficiency is common in individuals with Down syndrome.[44]

Conclusion

Individuals with Down syndrome have immune system dysregulation that causes alterations in the innate and adaptive immune system, which increases the prevalence of autoimmune and autoinflammatory conditions. These conditions may develop at any time throughout the lifespan, but many of them develop at an earlier age. As individuals with Down syndrome have increasing life expectancy, this may lead to increased disease burden. Immunotherapies increasingly target specific pathways, and recognition of the different mechanisms of immune dysregulation will lead to optimal therapy with minimal delay, which will improve outcomes for individuals with Down syndrome.

Claim Continuing Education Credit

To claim CME credits or ANCC contact hours for this reference article, you must enroll in our Learning Management System (LMS) and complete the required evaluation form to verify your participation.